Industry news that matters to you.  Learn more

KineMed Reports Clinical Data on Novel Method for Identifying and Verifying Biomarker Candidates in Cerebral Spinal Fluid for Parkinson’s Disease to the Michael J. Fox Foundation

At the Michael J. Fox Foundation grant review meeting held on November 1, 2010 in New York, KineMed reported clinical data on the Company’s discovery of a novel method for identifying and verifying biomarker candidates for Parkinson’s disease in cerebrospinal fluid (CSF). This discovery was made possible by KineMed’s proprietary isotopic labeling which reveals real-time deficits of microtubule-mediated neuronal transport.

Michael J. Fox Foundation Launches Parkinson’s Progression Markers Initiative (PPMI)

The Michael J. Fox Foundation has launched the Parkinson’s Progression Markers Initiative (PPMI) (www.michaeljfox.org/PPMI), the first-ever large-scale clinical study exclusively focused on identifying and validating Parkinson’s disease biomarkers.

CROs Join with MJFF for Parkinson’s Biomarker Research

Covance, Parexel and Epitomics are working with the Michael J Fox Foundation for Parkinson’s Research (MJFF) to develop biomarker candidates.

Initiation of the projects is part of efforts by MJFF to progress biomarker research. MJFF said there is “urgent need for an orchestrated, fieldwide strategy to drive tangible progress” in the sector and contract research organisations (CRO) have a role to play in this initiative.

Michael J. Fox Foundation Announces $1.1 Million to Advance Leading Biomarker Candidates for Parkinson’s Disease

The Michael J. Fox Foundation for Parkinson’s Research today announced nearly $1.1 million for projects aimed at advancing the development of leading biomarker candidates for Parkinson’s disease. The discovery and validation of biomarkers is of critical importance to increasing the speed and efficiency of PD therapeutic development, allowing scientists and clinicians to more accurately identify appropriate subjects for clinical studies, measure disease progression and monitor treatment effects in clinical trials.